Fundraising FoxCardinal Partners — 2015 Investments
2 investments dated 2015 · listed companies and verified rows first · show all
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Board seatPaul SchimmelJohn Clarke· per SEC Form D
Co-investorsEcoR1 CapitalSofinnova VenturesViking GlobalDomain AssociatesDomain PartnersPolaris Partners+2 more
Ivenix makes an intelligent infusion pump system for hospital settings that delivers intravenous medications to patients while incorporating safeguards to reduce medication errors.
BiotechHealthtechMedical DevicesAmesbury, US
John Sokolowski(Executive Officer)inGeorge W. Gray(Executive Officer)Carolyn Malleck(Executive Officer)inJesse Ambrosina(Executive Officer)
BoardKetan Patel(Director)inJohn K. Clarke(Director)in
Co-investorsF-Prime CapitalSCP Vitalife PartnersECO Fleet HoldingsWuXi Healthcare Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.